Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
GenScript
Secukinumab Monoclonal Antibody (22G7)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
图: 1 / 3
Secukinumab Antibody (A02152-40) in ELISA
Anti-Secukinumab Antibody (22G7) (GenScript, A02152-40) blocks Secukinumab binding with Human IL-17A recombinant protein. Coating antigen: Secukinumab 1 µg/mL. IL-17A final concentration: 1 µg/mL. Anti-Secukinumab antibody dilutions start from 30 μg/mL. IC50= 1.923 µg/mL.
产品信息
A02152-40
产品规格
种属反应
Human
宿主/亚型
Mouse
/ IgG1, kappa
分类
Monoclonal
类型
Antibody
克隆号
22G7
抗原
Secukinumab
偶联物
形式
Lyophilized
浓度
0.5 mg/mL
纯化类型
Protein A
保存液
PBS, pH 7.2
内含物
0.02% sodium azide
保存条件
-20°C, Avoid Freeze/Thaw Cycles
运输条件
Ambient (domestic); Wet ice (international)
产品详细信息
Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Competitive ELISA recommended dilution: 10-30 µg/mL
The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles.
靶标信息
Secukinumab (Cosentyx) is a human monoclonal antibody designed for the treatment of uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Secukinumab is an interleukin-17A (IL-17A) inhibitor marketed by Novartis. IL-17 is a group of proinflammatory cytokines released by cells of the immune system and exist in higher levels in many immune conditions associated with chronic inflammation. By targeting IL-17A, secukinumab has shown excellent efficacy in psoriasis by normalizing skin histology and was approved by the United States Food and pharmaceutical Administration on January 21, 2015 to treat adults with moderate-to-severe plaque psoriasis.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
